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Abstract
In this opinion, the GMO Panel assessed the ﬁve-event stack maize MON 87427 9 MON 89034 9
1507 9 MON 88017 9 59122 and its 25 subcombinations, independently of their origin. The GMO
Panel has previously assessed the ﬁve single events combined to produce this ﬁve-event stack maize
and 11 subcombinations of these events and did not identify safety concerns. No new data on the
single events or their previously assessed subcombinations, leading to modiﬁcation of the original
conclusions were identiﬁed. The combination of the single events and of the newly expressed proteins
in the ﬁve-event stack maize did not give rise to issues – based on the molecular, agronomic/
phenotypic or compositional characteristics – regarding food and feed safety and nutrition. Considering
the scope of this application, the known biological function of the newly expressed proteins and the
data available for the ﬁve-event stack maize and its previously assessed maize subcombinations, the
GMO Panel considered that different combinations of the single events would not raise environmental
concerns. The GMO Panel concludes that the ﬁve-event stack maize is as safe and as nutritious as the
non-genetically modiﬁed (GM) comparator and the tested non-GM reference varieties in the context of
its scope. For the 14 maize subcombinations for which no experimental data were provided, the
GMO Panel assessed the likelihood of interactions among the single events, and concluded that
their combinations would not raise safety concerns. Thesemaize subcombinations are therefore expected to
be as safe as the single events, the previously assessed subcombinations and maize MON 87427 9
MON 89034 9 1507 9 MON 88017 9 59122. Since the post-market environmental monitoring plan for
the ﬁve-event stack maize does not include any provisions for the 14 maize subcombinations not previously
assessed, the GMO Panel recommended the applicant to revise the plan accordingly.
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Summary
Following the submission of application EFSA-GMO-BE-2013-118 under Regulation (EC) No 1829/2003
from Monsanto Company (referred to hereafter as the applicant), the Panel on Genetically Modiﬁed
Organisms of the European Food Safety Authority (referred to hereafter as GMO Panel) was asked to
deliver a Scientiﬁc Opinion on the safety of genetically modiﬁed glufosinate-ammonium- and glyphosate-
tolerant and insect resistant maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122
(referred to hereafter as ‘ﬁve-event stack maize’) and its subcombinations independently of their origin,
according to the Commission Implementing Regulation (EU) No 503/2013 (referred to hereafter as
‘subcombinations’). The scope of application EFSA-GMO-BE-2013-118 is for the placing on the market of
maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 and all its subcombinations
independently of their origin for food and feed uses, import and processing.
The term ‘subcombination’ refers to any combination of up to four of the events present in the
ﬁve-event stack maize. The safety of subcombinations occurring as segregating progeny in the
harvested grains of maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 is evaluated in
the context of the assessment of the ﬁve-event stack maize in Section 3.3 of the present GMO
Panel Scientiﬁc Opinion. The safety of subcombinations that have either been, or could be produced by
conventional crossing through targeted breeding approaches, and which can be bred, produced and
marketed independently of the ﬁve-event stack, are risk assessed in the Section 3.4 of the present
GMO Panel Scientiﬁc Opinion.
In delivering its Scientiﬁc Opinion, the GMO Panel considered the data available on the single
events, the ﬁve-event stack maize, a four-event and two two-event stack subcombinations, the
scientiﬁc comments submitted by the Member States and the relevant scientiﬁc literature. The
ﬁve-event stack maize was produced by conventional crossing to combine ﬁve single maize events:
MON 87427 expressing the 5-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS) protein for
tolerance to glyphosate-containing herbicides; MON 89034 expressing the Cry1A.105 and Cry2Ab2
proteins which confer resistance to speciﬁc lepidopteran pests; 1507 expressing the Cry1F protein
which confers protection against speciﬁc lepidopteran pests and phosphinothricin acetyl transferase
(PAT) protein for tolerance to glufosinate-containing herbicides; MON 88017 expressing the Cry3Bb1
protein to confer protection against coleopteran pests belonging to the genus Diabrotica, such as the
western corn rootworm (Diabrotica virgifera virgifera) and CP4 EPSPS protein for tolerance to
glyphosate-containing herbicides; and 59122 expressing the Cry34Ab1 and Cry35Ab1 proteins to
confer protection against coleopteran pests belonging to the genus Diabrotica and the PAT protein for
tolerance to glufosinate-containing herbicides.
The GMO Panel evaluated the ﬁve-event stack maize and its subcombinations with reference to the
scope and appropriate principles described in its guidelines for the risk assessment of genetically
modiﬁed (GM) plants and derived food and feed, the environmental risk assessment of GM plants and
the post-market environmental monitoring of GM plants. The GMO Panel Guidance Documents
establish the principle that where all single events have been assessed, the risk assessment of stacked
events should focus mainly on issues related to (a) stability of the inserts, (b) expression of the
introduced genes and their products and (c) potential synergistic or antagonistic effects resulting from
the combination of the events (EFSA GMO Panel, 2011a).
For application EFSA-GMO-BE-2013-118, previous assessments of the ﬁve single maize events
(MON 87427, MON 89034, 1507, MON 88017 and 59122), the four-event stack maize MON 89034 9
1507 9 MON 88017 9 59122 and all its subcombinations and of the two two-event stack maize
events (1507 9 59122 and MON 89034 9 MON 88017) provided a basis to evaluate the ﬁve-event
stack maize and all its subcombinations. Maize MON 87427, MON 89034, 1507, MON 88017, 59122,
1507 9 59122, MON 89034 9 MON 88017 and MON 89034 9 1507 9 MON 88017 9 59122 (and all
its subcombinations) were previously assessed by the GMO Panel and no concerns on their safety were
identiﬁed. No safety issue concerning the ﬁve single maize events was identiﬁed by the updated
bioinformatic analyses, nor reported by the applicant since the publication of the previous GMO
Panel Scientiﬁc Opinions. Therefore, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
For the ﬁve-event stack maize, the risk assessment included the molecular characterisation of the
inserted DNA and analysis of protein expression. An evaluation of the comparative analyses of
agronomic/phenotypic and compositional characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food/feed were evaluated with respect to potential toxicity,
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allergenicity and nutritional characteristics. An evaluation of environmental impacts and post-market
environmental monitoring plans was also undertaken.
The molecular data establish that the events stacked in maize MON 87427 9 MON 89034 9
1507 9 MON 88017 9 59122 have retained their integrity. Protein expression analyses showed that
the levels of the newly expressed proteins are similar in the ﬁve-event stack maize and in the single
events except for the expected difference for the CP4 EPSPS and PAT protein levels resulting from the
combination of MON 87427 and MON 88017 single events, both producing CP4 EPSPS protein, and
1507 and 59122 single events, both producing PAT protein in the ﬁve-event stack. No indications of
interactions that may affect the integrity of the events and the levels of the newly expressed proteins
in this ﬁve-event stack maize were identiﬁed.
No relevant differences between maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122
and the non-GM comparator requiring further assessment regarding food and feed safety and
environmental impact were identiﬁed in grain and forage composition and in the tested agronomic and
phenotypic characteristics, except for a decrease of thiamin in the GM maize.
Based on the molecular, agronomic, phenotypic or compositional characteristics, the combination of
maize events MON 87427, MON 89034, 1507, MON 88017 and 59122 in the ﬁve-event stack maize did
not give rise to issues regarding food and feed safety and nutrition. The nutritional assessment
identiﬁed no concerns related to the decrease of thiamin. The combination of the newly expressed
proteins in the ﬁve-event stack maize did not raise concerns for human and animal health.
Considering the combined events, the outcome of the comparative analysis, the routes of exposure
and limited exposure levels, the GMO Panel concludes that this ﬁve-event stack maize would not raise
safety concerns in the event of accidental release of viable GM maize grains into the environment,
irrespective of possible interactions between the individual events within this ﬁve-event stack maize.
The GMO Panel concludes that the ﬁve-event stack maize is as safe and as nutritious as the
non-GM comparator and tested non-GM reference varieties in the context of the scope of this
application.
Since no new safety concerns were identiﬁed for the previously assessed maize MON 89034 9
MON 88017, MON 89034 9 MON 88017, MON 89034 9 1507 9 MON 88017 9 59122 and its
subcombinations, and no new data leading to the modiﬁcation of the original conclusions on safety were
identiﬁed, the GMO Panel considers that its previous conclusions on these maize subcombinations remain
valid. For the 14 maize subcombinations included in the scope of EFSA-GMO-BE-2013-118 for which no
experimental data were provided, the GMO Panel assessed the possibility of interactions between the
events, and concluded that different combinations of the events MON 87427, MON 89034, 1507,
MON 88017 and 59122 would not raise safety concerns. These maize subcombinations are therefore
expected to be as safe as the single events, the previously assessed maize subcombinations and the
ﬁve-event stack maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122.
Given the absence of safety concerns identiﬁed on food and feed derived from maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 and MON 89034 9 MON 88017, MON
89034 9 MON 88017, MON 89034 9 1507 9 MON 88017 9 59122 and its subcombinations, the GMO
Panel considers that post-market monitoring of these products is not necessary. However, the
post-market environmental monitoring (PMEM) plan submitted by the applicant for the ﬁve-event stack
maize does not include any provisions for the 14 subcombinations that were not previously assessed.
Therefore, the GMO Panel recommends the applicant to revise the plan accordingly.
Scientiﬁc opinion on application EFSA-GMO-BE-2013-118
www.efsa.europa.eu/efsajournal 4 EFSA Journal 2017;15(8):4921
Table of contents
Abstract.................................................................................................................................................. 1
Summary................................................................................................................................................ 3
1. Introduction................................................................................................................................ 6
1.1. Background ................................................................................................................................ 6
1.2. Terms of Reference as provided by the requestor .......................................................................... 7
2. Data and methodologies .............................................................................................................. 7
2.1. Data........................................................................................................................................... 7
2.2. Methodologies............................................................................................................................. 7
3. Assessment................................................................................................................................. 7
3.1. Introduction................................................................................................................................ 7
3.2. Updated information on the events............................................................................................... 9
3.3. Risk assessment of the ﬁve-event stack maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9
59122......................................................................................................................................... 10
3.3.1. Molecular characterisation............................................................................................................ 10
3.3.1.1. Genetic elements and their biological function ............................................................................... 10
3.3.1.2. Integrity of the events in the ﬁve-event stack maize MON 87427 9 MON 89034 9 1507 9 MON
88017 9 5912210 ....................................................................................................................... 12
3.3.1.3. Information on the expression of the inserts ................................................................................. 12
3.3.1.4. Conclusions of the molecular characterisation ................................................................................ 13
3.3.2. Comparative analysis ................................................................................................................... 13
3.3.2.1. Choice of comparator and production of material for the comparative analysis................................. 13
3.3.2.2. Agronomic and phenotypic characteristics ..................................................................................... 14
3.3.2.3. Compositional analysis ................................................................................................................. 15
3.3.2.4. Conclusions of the comparative analysis........................................................................................ 16
3.3.3. Food and feed safety assessment ................................................................................................. 16
3.3.3.1. Effects of processing ................................................................................................................... 16
3.3.3.2. Toxicology .................................................................................................................................. 16
3.3.3.3. Animal studies with the food/feed derived from GM plants ............................................................. 17
3.3.3.4. Allergenicity ................................................................................................................................ 17
3.3.3.5. Nutritional assessment of GM food/feed ........................................................................................ 18
3.3.3.6. Conclusion of the food and feed safety assessment ....................................................................... 18
3.3.4. Environmental risk assessment ..................................................................................................... 18
3.3.4.1. Persistence and invasiveness of the GM plant ................................................................................ 18
3.3.4.2. Potential for gene transfer ........................................................................................................... 19
3.3.4.3. Interactions of the GM plant with target organisms........................................................................ 20
3.3.4.4. Interactions of the GM plant with non-target organisms ................................................................. 20
3.3.4.5. Interactions with abiotic environment and biochemical cycles ......................................................... 21
3.3.4.6. Conclusion of the environmental risk assessment ........................................................................... 21
3.3.5. Conclusion on the ﬁve-event stack maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9
59122......................................................................................................................................... 21
3.4. Risk assessment of the subcombinations ....................................................................................... 22
3.4.1. Subcombinations previously assessed ........................................................................................... 22
3.4.2. Subcombinations not previously assessed...................................................................................... 22
3.4.2.1. Stability of the events .................................................................................................................. 22
3.4.2.2. Expression of the events.............................................................................................................. 23
3.4.2.3. Potential functional interactions between the events ...................................................................... 23
3.4.3. Conclusion .................................................................................................................................. 23
3.5. Post-market monitoring................................................................................................................ 24
3.5.1. Post-market monitoring of GM food/feed....................................................................................... 24
3.5.2. Post-market environmental monitoring.......................................................................................... 24
4. Overall conclusions and recommendations..................................................................................... 24
References.............................................................................................................................................. 26
Abbreviations .......................................................................................................................................... 29
Appendix A – Protein expression data ....................................................................................................... 30
Scientiﬁc opinion on application EFSA-GMO-BE-2013-118
www.efsa.europa.eu/efsajournal 5 EFSA Journal 2017;15(8):4921
1. Introduction
1.1. Background
On 26 November 2013, the European Food Safety Authority (EFSA) received from the Competent
Authority of Belgium application EFSA-GMO-BE-2013-118, for authorisation of genetically modiﬁed
(GM) insect-resistant and herbicide-tolerant maize MON 87427 9 MON 89034 9 1507 9 MON
88017 9 59122 (referred to hereafter as ﬁve-event stack maize), submitted by Monsanto Europe S.A./N.V.
(referred to hereafter as the applicant) within the framework of Regulation (EC) No 1829/20031, for food
and feed uses, import and processing. The risk assessment of application EFSA-GMO-BE-2013-118
presented here is for the placing on the market of ﬁve-event stack maize and all its subcombinations
independently of their origin, for food and feed uses, import and processing (see Table 1).
After receiving application EFSA-GMO-BE-2013-118 and in accordance with Articles 5(2)(b) and 17
(2)(b) of Regulation (EC) No 1829/2003, EFSA informed Member States and the European
Commission, and made the summary of the application available to the public on the EFSA website.2
EFSA initiated a formal review of the application to check compliance with the requirements laid down
in Articles 5(3) and 17(3) of Regulation (EC) No 1829/2003. EFSA requested additional information
under completeness check on 17 January 2014 and received it on 17 February 2014. On
10 March 2014, EFSA declared the application valid in accordance with Articles 6(1) and 18(1) of
Regulation (EC) No 1829/2003. The clock of the application was stopped from 13 March 2014 to
27 May 2015 due to the pending assessment of the single-event maize MON 87427 (application
reference EFSA-GMO-BE-2012-110).
EFSA made the valid application available to Member States and the European Commission, and
consulted nominated risk assessment bodies of Member States, including national Competent Authorities
within the meaning of Directive 2001/18/EC3 following the requirements of Articles 6(4) and 18(4) of
Regulation (EC) No 1829/2003, to request their scientiﬁc opinion. Member States had 3 months after the
date of receipt of the valid application (until 11 September 20154) to make their opinion known.
The GMO Panel carried out the scientiﬁc risk assessment of the ﬁve-event stack maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 and subcombinations (referred to as
‘subcombinations independently of their origin’ according to the Commission Implementing Regulation (EU)
No 503/20135). The GMO Panel requested additional information from the applicant on 11 June 2015,
30 July 2015, 26 November 2015, 11 December 2015, 8 March 2016, 28 June 2016, 4 August 2016,
11 August 2016, 25 October 2016, 11 April 2017 and 16 May 2017. The applicant provided the requested
information on 6 July 2015, 2 October 2015, 18 December 2015, 13 June 2016, 11 July 2016, 29 July
2016, 1 September 2016, 15 September 2016, 24 November 2016, 25 November 2016, 6 June 2017 and
20 June 2017, respectively. The applicant provided additional information spontaneously on 25 November
2016 and 13 December 2016.
In the context of contract OC/EFSA/UNIT/GMO/2013/01 and OC/EFSA/UNIT/GMO/2014/01, the
contractors performed preparatory work and delivered reports on the methods applied by the applicant
in performing bioinformatic analyses and statistical analyses, respectively.
In giving its Scientiﬁc Opinion to the European Commission, Member States and the applicant, and
in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA has endeavoured
to respect a time limit of 6 months from the acknowledgement of the valid application. As additional
information was requested by the GMO Panel, the time limit of 6 months was extended accordingly, in
line with Articles 6(1), 6(2), 18(1), and 18(2) of Regulation (EC) No 1829/2003.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation, and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. Ofﬁcial Journal of the European Communities, L268, 1–23.
2 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2013-00926
3 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
4 The Member States’ commenting period of application EFSA-GMO-BE-2013-118 was suspended until the clock of the
application was re-started following the adoption of the Scientiﬁc Opinion of application EFSA-GMO-BE-2012-110 (authorisation
of GM maize MON 87427).
5 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically
modiﬁed food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and
amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L157, 8.6.2013, p. 1–48.
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1.2. Terms of Reference as provided by the requestor
The GMO Panel was asked to carry out a scientiﬁc assessment of ‘maize MON 87427 9
MON 89034 9 1507 9 MON 88017 9 59122 and all maize subcombinations of the individual events
independently of their origin (as present in the segregating progeny as well as independent stacks to
be placed on the market as such)’, for food and feed uses, import and processing in accordance with
Articles 6(6) and 18(6) of Regulation (EC) No 1829/2003. The risk assessment of application EFSA-
GMO-BE-2013-118 presented here is for the placing on the market of glyphosate- and glufosinate-
tolerant and insect-resistant maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 and all
its subcombinations, independently of their origin, for food and feed uses, import and processing.
Where applicable, any conditions or restrictions which should be imposed on the placing on the
market and/or speciﬁc conditions or restrictions for use and handling, including post-market monitoring
requirements based on the outcome of the risk assessment and, in the case of genetically modiﬁed
organisms (GMOs) or food/feed containing or consisting of GMOs, conditions for the protection of
particular ecosystems/environment and/or geographical areas should be indicated in accordance with
Articles 6(5)(e) and 18(5)(e) of Regulation (EC) No 1829/2003.
The GMO Panel was not requested to give an opinion on information required under Annex II to
the Cartagena Protocol. Furthermore, the GMO Panel did not consider proposals for labelling and
methods of detection (including sampling and the identiﬁcation of the speciﬁc transformation event in
the food/feed and/or food/feed produced from it), which are matters related to risk management.
2. Data and methodologies
2.1. Data
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-BE-2013-118,
additional information provided by the applicant, scientiﬁc comments submitted by the Member States
and relevant scientiﬁc publications.
2.2. Methodologies
The GMO Panel carried out a scientiﬁc risk assessment of maize MON 87427 9
MON 89034 9 1507 9 MON 88017 9 59122 and all its subcombinations independently of their origin
(see Table 1), for food and feed uses, import and processing in accordance with Articles 6(6) and 18(6)
of Regulation (EC) No 1829/2003. The GMO Panel took into account the appropriate principles described
in its guidelines for the risk assessment of GM plants and derived food and feed (EFSA GMO Panel,
2011a), for the environmental risk assessment (ERA) of GM plants (EFSA GMO Panel, 2010a) and for the
post-market environmental monitoring (PMEM) of GM plants (EFSA GMO Panel, 2011b).
The comments raised by Member States are addressed in Annex G of EFSA’s overall opinion and
were taken into consideration during the scientiﬁc risk assessment.
3. Assessment
3.1. Introduction
Application EFSA-GMO-BE-2013-118 covers the ﬁve-event stack maize MON 87427 9
MON 89034 9 1507 9 MON 88017 9 591226 and all its subcombinations independently of their origin
(Table 1). The scope of this application is for food and feed uses, import and processing, and excludes
cultivation within the European Union (EU).
The term ‘subcombination’ refers to any combination of up to four of the events present in the
ﬁve-event stack maize.
The safety of subcombinations occurring as segregating progeny in the harvested grains of maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 is evaluated in the context of the
assessment of the ﬁve-event stack maize in Section 3.3 of the present GMO Panel Scientiﬁc Opinion.
‘Subcombination’ also covers combinations of up to four of the ﬁve events MON 87427,
MON 89034, 1507, MON 88017 or 59122 that have either been, or could be produced by conventional
crossing through targeted breeding approaches (EFSA GMO Panel, 2011a). These are maize stacks
6 Unique identiﬁer: MON-87427-7 9 MON-89Ø34-3 9 DAS-Ø15Ø7-1 9 MON-88Ø17-3 9 DAS-59122-7.
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that can be bred, produced and marketed independently of the ﬁve-event stack maize. These stacks
are risk assessed in the Section 3.4 of this GMO Panel Scientiﬁc Opinion.
The ﬁve-event stack maize was produced by conventional crossing to combine ﬁve single maize
events: MON 87427 (expressing the 5-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS)
protein); MON 89034 (expressing the Cry1A.105 and Cry2Ab2 proteins); 1507 (expressing the Cry1F
and phosphinothricin acetyl transferase (PAT) proteins); MON 88017 (expressing the Cry3Bb1 and
CP4 EPSPS proteins); 59122 (expressing the Cry34Ab1, Cry35Ab1 and PAT proteins).
Herbicidal tolerance traits are achieved by the expression of CP4 EPSPS protein from Agrobacterium
sp. strain CP4 and PAT protein from Streptomyces viridochromogenes. Insecticidal resistance traits are
achieved by the expression of the Cry1A.105, Cry2Ab2 and Cry1F proteins from Bacillus thuringiensis
subsp. kurstaki and subsp. aizawai, which confer protection against speciﬁc lepidopteran pests, such
as the European corn borer (Ostrinia nubilalis) and by the expression of the Cry3Bb1, Cry34Ab1 and
Cry35Ab1 from B. thuringiensis (strain PS149B1), which confers protection against speciﬁc coleopteran
pests belonging to the genus Diabrotica, such as the Western corn rootworm (Diabrotica virgifera
virgifera).
All ﬁve single maize events, two-event stacks 1507 9 59122 and MON 89034 9 MON 88017 as
well as the four-event stack maize MON 89034 9 1507 9 MON 88017 9 59122 and all its
subcombinations independently of their origin have been previously assessed by the GMO Panel (see
Table 2), and no safety concerns were identiﬁed.
Table 1: Stacked maize events covered by the scope of application EFSA-GMO-BE-2013-118
Degree of stacking Events
Five-event stack maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122
Four-event stack maize MON 89034 9 1507 9 MON 88017 9 59122
MON 87427 9 1507 9 MON 88017 9 59122
MON 87427 9 MON 89034 9 1507 9 59122
MON 87427 9 MON 89034 9 1507 9 MON 88017
MON 87427 9 MON 89034 9 MON 88017 9 59122
Three-event stack maize 1507 9 MON 88017 9 59122
MON 89034 9 1507 9 59122
MON 89034 9 1507 9 MON 88017
MON 89034 9 MON 88017 9 59122
MON 87427 9 1507 9 59122
MON 87427 9 1507 9 MON 88017
MON 87427 9 MON 88017 9 59122
MON 87427 9 MON 89034 9 1507
MON 87427 9 MON 89034 9 59122
MON 87427 9 MON 89034 9 MON 88017
Two-event stack maize 1507 9 59122
MON 88017 9 59122
MON 89034 9 1507
MON 89034 9 59122
MON 89034 9 MON 88017
1507 9 MON 88017
MON 87427 9 1507
MON 87427 9 59122
MON 87427 9 MON 88017
MON 87427 9 MON 89034
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EFSA guidance establishes the principle that ‘For GM plants containing a combination of
transformation events (stacked events) the primary concern for risk assessment is to establish that the
combination of events is stable and that no interactions between the stacked events, that may raise
safety concerns compared to the single events, occur. The risk assessment of GM plants containing
stacked events focuses on issues related to: (a) stability of the inserts, (b) expression of the
introduced genes and their products and (c) potential synergistic or antagonistic effects resulting from
the combination of the events’ (EFSA GMO Panel, 2011a).
3.2. Updated information on the events
Since the publication of the scientiﬁc opinions on the single maize events by the GMO Panel (see
Table 2), no safety issue concerning the ﬁve single events has been reported by the applicant. The
applicant clariﬁed that the 59122 maize sequence reported for the ﬁve-event stack maize was the
sequence submitted in the original application EFSA-GMO-NL-2005-12 (EFSA, 2007), but corrected for
sequencing errors affecting three single nucleotides7 (EFSA GMO Panel, 2016). In addition, the
applicant clariﬁed that the 1507 maize sequence reported for the ﬁve-event stack maize contained two
nucleotide changes in the insert sequence compared to the original, corrected 1507 maize sequence
(EFSA GMO Panel, 2017a). Analysis of the new sequencing data and the bioinformatic analyses
performed on the new sequence did not give rise to speciﬁc safety issues.8,9
Updated bioinformatic analyses on the junction regions for events MON 87427, MON 89034, 1507,
MON 88017 and 59122 conﬁrmed that no known endogenous genes were disrupted by any of the
inserts.7,8,10 Updated bioinformatic analyses of the amino acid sequence of the newly expressed
Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS proteins revealed no
signiﬁcant similarities to toxins and allergens.7,8,10 In addition, updated bioinformatic analyses of the
Table 2: Single maize events and subcombinations of maize MON 87427 9 MON 89034 9 1507 9
MON 88017 9 59122 previously assessed by the GMO Panel
Event Application or mandate EFSA Scientiﬁc Opinion
MON 87427 EFSA-GMO-BE-2012-110 EFSA GMO Panel (2015)
MON 89034 EFSA-GMO-NL-2007-37 EFSA (2008)
1507 C/NL/00/10 EFSA (2004)
C/ES/01/01,2001/18/EC EFSA (2005a)
EFSA-GMO-NL-02 EFSA (2005b)
EFSA-GMO-RX-1507 EFSA (2009)
EFSA-GMO-RX-001 EFSA GMO Panel (2017a)
MON 88017 EFSA-GMO-CZ-2007-27 EFSA GMO Panel (2009a)
59122 EFSA-GMO-NL-2005-12 EFSA (2007)
EFSA-GMO-NL-2005-23 EFSA GMO Panel (2013a,b)
EFSA-GMO-RX-003 EFSA GMO Panel (2017b)
1507 9 59122 EFSA-GMO-NL-2005-15 EFSA GMO Panel (2009b)
MON 89034 9 MON 88017 EFSA-GMO-NL-2007-39 EFSA GMO Panel (2010b)
MON 88017 9 59122 EFSA-GMO-CZ-2008-62 EFSA GMO Panel (2010c)
1507 9 MON 88017 EFSA-GMO-CZ-2008-62 EFSA GMO Panel (2010c)
MON 89034 9 1507 EFSA-GMO-CZ-2008-62 EFSA GMO Panel (2010c)
MON 89034 9 59122 EFSA-GMO-CZ-2008-62 EFSA GMO Panel (2010c)
1507 9 MON 88017 9 59122 EFSA-GMO-CZ-2008-62 EFSA GMO Panel (2010c)
MON 89034 9 1507 9 59122 EFSA-GMO-CZ-2008-62 EFSA GMO Panel (2010c)
MON 89034 9 1507 9 MON 88017 EFSA-GMO-CZ-2008-62 EFSA GMO Panel (2010c)
MON 89034 9 MON 88017 9 59122 EFSA-GMO-CZ-2008-62 EFSA GMO Panel (2010c)
MON 89034 9 1507 9 MON 88017 9 59122 EFSA-GMO-CZ-2008-62 EFSA GMO Panel (2010c)
7 Additional information: 15/9/2016 and 24/11/2016.
8 Additional information: 25/11/2016.
9 Additional information: 20/6/2017.
10 Additional information: 29/7/2016.
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newly created Open Reading Frames (ORFs) within the inserts and at their junctions for events
MON 87427, MON 89034, 1507, MON 88017 and 59122 to identify any ORFs with signiﬁcant similarity
to toxins or allergens that were not previously assessed, revealed that, for event MON 89034, a single
ORF exceeded the allergenicity assessment threshold of 35% identity using an 80 amino acid sliding
window approach. This ORF is found within the transcriptional unit of the Cry2Ab2 coding sequence
driven by the Figwort Mosaic Virus 35S promoter. It is in the same orientation but in a different
reading frame to the Cry2Ab2 ORF and does not contain any in-frame translational start codons
(ATG).11 In conclusion, these analyses indicated that the expression of an ORF showing signiﬁcant
similarities to toxins or allergens for any of the events in maize MON 87427 9 MON 89034 9
1507 9 MON 88017 9 59122 is highly unlikely.
In order to assess the possibility for horizontal gene transfer (HGT) by homologous recombination
(HR), the applicant performed a sequence identity analysis for events MON 87427, MON 89034, 1507,
MON 88017 and 59122 to microbial DNA. The likelihood and potential consequences of plant-to-
bacteria gene transfer are described in Section 3.3.4.
Based on the above information, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
3.3. Risk assessment of the ﬁve-event stack maize MON 87427 3 MON
89034 3 1507 3 MON 88017 3 59122
3.3.1. Molecular characterisation
Possible interactions affecting the integrity of the events, protein expression levels or the biological
functions conferred by the individual inserts are considered.
3.3.1.1. Genetic elements and their biological function12
Maize events MON 87427, MON 89034, 1507, MON 88017 and 59122 were combined by
conventional crossing to produce event MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122.
The structure of the inserts introduced into maize MON 87427, MON 89034, 1507, MON 88017 and
59122 is described in detail in the respective EFSA scientiﬁc opinions (Table 2) and no new genetic
modiﬁcations were involved. Genetic elements in the expression cassettes of the single events are
summarised in Table 3.
Intended effects of the inserts in maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122
are summarised in Table 4.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseen interactions at the biological level are between the Cry proteins in susceptible insects.
Table 3: Genetic elements in the expression cassettes of the events stacked in maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122
Event Promoter 50 UTR
Transit
peptide
Coding region Terminator
MON 87427 35S (CaMV) – CTP2
(Arabidopsis
thaliana)
CP4 epsps*
(Agrobacterium sp.)
nos
(Agrobacterium
tumefaciens)
MON 89034 35S (CaMV) CAB
(Triticum
sp.)
– cry1A.105
(Bacillus thuringiensis)
hsp17 (Triticum sp.)
35S (FMV) – CTP
(Z. mays)
cry2Ab2
(B. thuringiensis)
nos (A. tumefaciens)
1507 ubiZM1 (Zea
mays)
– – cry1F
(B. thurigiensis)
ORF25PolyA
(A. tumefaciens)
35S (CaMV) – – pat
(Streptomyces
viridochromogenes)
35S (CaMV)
11 Additional information: 6/6/2017.
12 Dossier: Part II – Section A2.2.2.
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Event Promoter 50 UTR
Transit
peptide
Coding region Terminator
MON 88017 act1
(Oryza sativa)
– CTP2
(A. thaliana)
CP4 epsps*
(Agrobacterium sp.)
nos
(A. tumefaciens)
35S (CaMV) CAB
(Triticum
sp.)
– Cry3Bb1
(B. thuringiensis)
hsp17
(Triticum sp.)
59122 ubiZM1
(Z. mays)
– – cry34Ab1
(B. thuringiensis)
pinII
(Solanum tuberosum)
wheat
peroxidase
(Triticum
aestivum)
– – cry35Ab1
(B. thuringiensis)
pinII
(S. tuberosum)
35S (CaMV) – – pat
(S. viridochromogenes)
35S (CaMV)
CaMV: cauliﬂower mosaic virus; UTR: untranslated region; CTP: chloroplast transit peptide.
(–): When no element was speciﬁcally introduced to optimise expression.
Table 4: Characteristics and intended effects of the events stacked in maize MON 87427 9 MON
89034 9 1507 9 MON 88017 9 59122
Event Protein
Donor organism and biological
function
Intended effects in GM plant
MON 87427 CP4 EPSPS Donor organism: Agrobacterium strain
CP4. 5-enolpyruvylshikimate-3-
phosphate synthase (EPSPS) is an
enzyme involved in the shikimic acid
pathway for aromatic amino acid
biosynthesis in plants and
microorganisms (Herrmann, 1995)
The expression of the bacterial
CP4 EPSPS in event MON 87427 confers
tolerance to glyphosate-containing
herbicides as it has lower afﬁnity
towards glyphosate than the plant
endogenous enzyme
MON 89034 Cry1A.105
Cry2Ab2
Donor organism: B. thuringiensis
subsp. kurstaki and subsp. aizawai.
B. thuringiensis is an insect pathogen;
its insecticidal activity is attributed to
the expression of crystal protein (cry)
genes (Schnepf et al., 1998)
Donor organism: B. thuringiensis
subsp. kurstaki. B. thuringiensis is an
insect pathogen; its insecticidal activity
is attributed to the expression of crystal
protein (cry) genes
Event MON 89034 expresses a modiﬁed
Bacillus thuringiensis
Cry1A-type protein with overall amino
acid sequence identity of 93.4%, 90%,
and 76.7% to the Cry1Ac, Cry1Ab and
Cry1F, respectively. Cry1A.105 is a
protein toxic to certain lepidopteran
larvae
Event MON 89034 expresses the
Cry2Ab2 protein, which is toxic to
certain lepidopteran larvae
1507 Cry1F
PAT
Donor organism: Bacillus thuringiensis
subsp. aizawai. B. thuringiensis is an
insect pathogen; its insecticidal activity
is attributed to the expression of crystal
protein (cry) genes
Donor organism:
Streptomyces viridochromogenes strain
T€u494
Phosphinothricin-acetyl-transferase
(PAT) enzyme confers resistance to the
antibiotic bialaphos (Wohlleben et al.,
1988)
Event 1507 expresses a truncated cry1F
gene which was modiﬁed to enhance
expression in plants. The amino acid
sequence of the truncated part was not
modiﬁed except for a single amino acid
substitution, phenylalanine to leucine at
position 604. Cry1F is a protein toxic to
certain lepidopteran larvae
Event 1507 expressed PAT, which
acetylates L-glufosinate-ammonium and
thereby confers tolerance to glufosinate
ammonium-containing herbicides
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3.3.1.2. Integrity of the events in the ﬁve-event stack maize MON 87427 3 MON
89034 3 1507 3 MON 88017 3 5912210
The genetic stability of the inserted DNA over multiple generations in single maize events
MON 87427, MON 89034, 1507, MON 88017 and 59122 was demonstrated previously (see Table 2).
Integrity of these events in maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 was
demonstrated by Southern analyses.
3.3.1.3. Information on the expression of the inserts13
Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS protein levels were
analysed by enzyme-linked immunosorbent assay (ELISA) in material harvested from replicated ﬁeld
trials at ﬁve locations in the US in the 2010 growing season.
Samples analysed included leaf (V2–V4), root (V2–V4 and R5), whole plant (V10–V12), forage (R5),
pollen (pollination) and grain (R6) both those treated and not treated with glyphosate and/or
glufosinate. Since grain and forage are the main raw commodities used for food and feed
purposes, protein levels in these commodities from maize MON 87427 9 MON 89034 9 1507 9
MON 88017 9 59122 (the highest mean values, regardless the treatment) are summarised in Table 5.
Event Protein
Donor organism and biological
function
Intended effects in GM plant
MON 88017 CP4 EPSPS
Cry3Bb1
Donor organism: Agrobacterium strain
CP4. 5-enolpyruvylshikimate-3-
phosphate synthase (EPSPS) is an
enzyme involved in the shikimic acid
pathway for aromatic amino acid
biosynthesis in plants and
microorganisms
Donor organism: B. thuringiensis
subsp. kumamotoensis. B. thuringiensis
is an insect pathogen; its insecticidal
activity is attributed to the expression
of crystal protein (cry) genes (Ellis
et al., 2002)
The expression of the bacterial CP4
EPSPS in event MON 88017 confers
tolerance to glyphosate-containing
herbicides as it has lower afﬁnity
towards glyphosate than the plant
endogenous enzyme
Event MON 88017 expresses the
Cry3Bb1 protein, which is toxic to
certain lepidopteran larvae
59122 Cry34Ab1
Cry35Ab1
PAT
Donor organism: B. thuringiensis strain
PS149B1. B. thuringiensis is an insect
pathogen; its insecticidal activity is
attributed to the expression of crystal
protein (cry) genes
Donor organism: B. thuringiensis strain
PS149B1. B. thuringiensis is an insect
pathogen; its insecticidal activity is
attributed to the expression of crystal
protein (cry) genes
Donor organism:
Streptomyces viridochromogenes.
Phosphinothricin-acetyl-transferase
(PAT) enzyme confers resistance to the
antibiotic bialaphos
Event 59122 expresses a cry34Ab1
gene which was modiﬁed to enhance
expression in plants. The amino acid
sequence was not modiﬁed. Cry34Ab1
is a protein toxic to certain coleopteran
larvae feeding on maize
Event 59122 expresses a cry35Ab1
gene which was modiﬁed for enhanced
expression in plants. The amino acid
sequence was not modiﬁed. The
Cry35Ab1 protein is toxic to certain
coleopteran larvae feeding on maize
Event 59122 expressed PAT, which
acetylates L-glufosinate-ammonium and
thereby confers tolerance to glufosinate
ammonium-containing herbicides
13 Dossier: Part II – Section A2.2.3, study MSL0024204; additional information: 18/12/2015.
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In order to assess the changes in protein expression levels that may result from potential
interactions between the events, protein levels were determined for the ﬁve-event stack maize and the
corresponding single events in different parts of the plant.
The levels of all the newly expressed proteins in the ﬁve-event stack maize and the corresponding
singles were similar in all tissues except for the expected difference for the CP4 EPSPS and PAT protein
levels resulting from the combination of MON 87427 and MON 88017 single events, both producing
CP4 EPSPS protein, and 1507 and 59122 single events, both producing PAT protein in the ﬁve-event
stack maize (Appendix A). Therefore, there is no indication of interactions that may affect the levels of
the newly expressed proteins in this stack.
3.3.1.4. Conclusions of the molecular characterisation
The molecular data establish that the events stacked in maize MON 87427 9 MON 89034 9
1507 9 MON 88017 9 59122 have retained their integrity. Protein expression analyses showed that
the levels of the newly expressed proteins are similar in the ﬁve-event stack maize and in the single
events except for CP4 EPSPS and PAT which showed the expected higher levels in the stack resulting
from the combination of MON 87427 and MON 88017 (producing CP4 EPSPS) and 1507 and 59122
(producing PAT) events. Therefore, there is no indication of an interaction between the events that
may affect their integrity and the levels of the newly expressed proteins in this stack.
Based on the known biological function of the newly expressed proteins, the only foreseen
interactions at the biological level are between the Cry proteins in susceptible insects (Cry1A.105,
Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1 and Cry35Ab1), which will be dealt with in Section 3.3.4.
3.3.2. Comparative analysis
3.3.2.1. Choice of comparator and production of material for the comparative analysis14
Application EFSA-GMO-BE-2013-118 presents data on agronomic and phenotypic characteristics,
as well as on forage and grain composition of the ﬁve-event stack maize MON 87427 9
MON 89034 91507 9 MON 88017 9 59122 derived from ﬁeld trials performed in the US in 2010
(Table 6).
Table 5: Means, standard deviations and ranges of protein levels (lg/g dry weight) in grains
(n = 19 or n = 20) and forage (n = 20) from maize MON 87427 9 MON 89034 9
1507 9 MON 88017 9 59122
Protein
Tissue/developmental stage
Grain/R6 Forage/R5
CP4 EPSPS 7.6(a)  1.1(b)
(5.8–11)(c)
190  50
(100–270)
Cry1A.105 8.1  2.4
(6.0–14)
32  8.6
(16–45)
Cry2Ab2 1.8  0.40
(1.2–2.8)
39  10.0
(17–58)
Cry1F 2.0  0.33
(1.6–2.8)
5.0  1.2
(3.1–7.3)
PAT ˂ LOD(d) 0.85  0.30
(0.17–1.1)
Cry3Bb1 7.8  1.1
(6.1–9.6)
50  11
(30–69)
Cry34Ab1 35  4.3
(29–42)
99  23
(66–160)
Cry35Ab1 0.55  0.11
(0.39–0.80)
12  3.2
(6.9–18)
(a): Mean.
(b): Standard deviation.
(c): Range.
(d): LOD: limit of detection.
14 Dossier: Part II – Sections A3.1 and A3.2; additional information: 2/10/2015, 13/6/2016, 11/7/2016 and 1/9/2016.
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The ﬁeld trials were conducted in major maize growing areas of the US,15 representing regions of
diverse agronomic practices and environmental conditions. At each site, the following materials were
grown in a randomised complete block design with four replicates: maize MON 87427 9 MON 89034
9 1507 9 MON 88017 9 59122, a non-GM comparator (maize EXP262) and four non-GM maize
reference varieties, all treated (sprayed) with plant protection products according to local
requirements, and maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 treated with the
intended herbicides, in addition to plant protection products. A total of 2816 and 2417 non-GM maize
reference varieties were included in the agronomic and phenotypic and compositional analysis,
respectively. The comparator used in the agronomic/phenotypic and compositional ﬁeld trials is a non-
GM maize line (EXP262 [= HCL301 9 LH287]) with a genetic background similar to that of the
ﬁve-event stack maize, as documented by the pedigree, and was therefore considered to be an
appropriate non-GM comparator by the GMO Panel.
Statistical analysis of ﬁeld trials data
The statistical analysis of the agronomic, phenotypic and compositional data from the 2010 ﬁeld
trials followed the recommendations of the GMO Panel (EFSA GMO Panel, 2010d, EFSA GMO Panel,
2011a). This included, for each of the two treatments of maize MON 87427 9 MON 89034
9 1507 9 MON 88017 9 59122, the application of a difference test (between the GM maize and the
non-GM comparator) and an equivalence test (between the GM maize and the set of non-GM maize
reference varieties). The results of the equivalence test are categorised into four possible outcomes
(I–IV, ranging from equivalence to non-equivalence).18
3.3.2.2. Agronomic and phenotypic characteristics
Agronomic and phenotypic characteristics tested under ﬁeld conditions19
The agronomic and phenotypic endpoints evaluated in the 2010 ﬁeld trials were: early stand count,
days to 50% pollen shed, days to 50% silking, stay green, ear height, plant height, dropped ear
count, stalk lodged plants, root lodged plants, ﬁnal stand count, grain moisture, test weight, yield, and
visually observable responses to naturally occurring diseases, arthropod damage and abiotic stressors.
Two of the 16 endpoints evaluated (dropped ear count and root lodged plants) were not subject to
a formal statistical analysis due to the lack of variability in the data.
Table 6: Overview of comparative analysis studies with maize MON 87427 9 MON 89034 9
1507 9 MON 88017 9 59122 provided in application EFSA-GMO-BE-2013-118
Study focus Study details Comparator
Commercial non-GM
maize reference
varieties(a)
Agronomic and phenotypic
characteristics
Field trials, 2010, US, nine locations Maize EXP262 Twenty-eight
Compositional analysis Field trials, 2010, US, eight locations Maize EXP262 Twenty-four
non-GM: non-genetically modiﬁed.
(a): Four different varieties were grown at each location.
15 The sites for the agronomic and phenotypic ﬁeld trials were in Jackson (AR); Hardin (IA); Greene (IA); Clinton (IL); Stark (IL);
Boone (IN); Pawnee (KS); York (NE); and Miami (OH). The sites for the compositional analysis ﬁeld trials were in Jackson
(AR); Greene (IA); Jefferson (IA); Clinton (IL); Stark (IL); Boone (IN); Pawnee (KS); and York (NE).
16 Burrus 645, Cornbelt 96043, DKC 60-15, DKC 61-50, DKC62-30, Fielder’s Choice NG6778, Fontanelle 4924, H-9180, iCorn
110.M7, Kruger K-0210, Legacy L6600, Legacy L6673, Lewis 6014, Lewis 7007, Midland Phillips 799, Midland Phillips 7B15P,
Midwest Genetics 78130, Mycogen 2M746, NC+ 5411, NK N64Z, NK N72-G8, Pioneer 32B81, Pioneer 32T16, Pioneer 33T56,
Specialty 4672A, Stewart S518, Stewart S588 and Triumph 1416.
17 Burrus 645, Cornbelt x6043, DKC60-15, DKC61-50, Fielder’s Choice NG6778, Fontanelle 4924, H-9180, iCorn 110.M7, Legacy
L6600, Legacy L6673, Lewis 7007, Midland Phillips 799, Midland Phillips 7B15P, Midwest Genetics 78130, Mycogen 2M746,
NC+ 5411, NK N72-G8, Pioneer 32B81,Pioneer 32T16, Pioneer 33T56, Specialty 4672A, Stewart S518, Stewart S588 and
Triumph 1416.
18 In detail, the four outcomes are: category I (indicating full equivalence to the non-GM reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and
category IV (indicating non-equivalence).
19 Dossier: Part II – Section A3.4; additional information: 2/10/2015, 13/6/2016, 11/7/2016 and 1/9/2016.
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Statistically signiﬁcant differences between the ﬁve-event stack maize not treated with the intended
herbicides and the non-GM comparator were identiﬁed for: early stand count, ear height, plant height,
stalk lodged plants, grain moisture and test weight; and between the ﬁve-event stack maize treated with
the intended herbicides and the non-GM comparator for: days to 50% pollen shed, days to 50% silking,
ear height, plant height, stalk lodged plants, grain moisture and test weight. Except for stalk lodged
plants, for which the test of equivalence could not be applied (because the variation between the non-GM
reference varieties was estimated to be zero), all these endpoints fell under equivalence category I.
Given the magnitude of the observed differences, the outcome of the equivalence test and the nature
of the endpoints, the GMO Panel considered that none of the agronomic and phenotypic differences
between the ﬁve-event stack maize and the non-GM comparator were relevant for further assessment.
3.3.2.3. Compositional analysis20
Forage and grain harvested from the ﬁeld trials in the US in 2010 (Table 6) were analysed for 78
different constituents (9 in forage and 69 in grain), including the key constituents recommended by
the OECD (OECD, 2002). For 15 grain components,21 more than 50% of the observations were below
the limit of quantiﬁcation. The statistical analysis was applied to the remaining 63 constituents (9 in
forage22 and 54 in grain23).
The test of equivalence could not be applied to acid detergent ﬁbre (ADF) in forage because the
variation between the non-GM commercial reference varieties was estimated to be zero. A signiﬁcant
difference for ADF in forage was identiﬁed between MON 87427 9 MON 89034 9 1507 9 MON
88017 9 59122 (treated) and the non-GM comparator.24
The combination of test of difference and test of equivalence could be applied to the remaining 62
endpoints (forage and grain), with the following results:
• Statistically signiﬁcant differences between maize MON 87427 9 MON 89034 9 1507
9 MON 88017 9 59122 (not treated) and the non-GM comparator were identiﬁed for 47
endpoints.25 All the endpoints fell under equivalence category I or II.
• Statistically signiﬁcant differences between maize MON 87427 9 MON 89034 9 1507 9
MON 88017 9 59122 (treated) and the non-GM comparator were identiﬁed for 50 endpoints.26
All the endpoints fell under equivalence category I except for thiamin levels which fell under
category III.27
The GMO Panel assessed all the compositional differences between maize MON 87427 9 MON
89034 9 1507 9 MON 88017 9 59122 and the non-GM comparator. After considering the known
biological role of the compounds, the outcome of the equivalence test and the magnitude of the
20 Dossier: Part II – Section A3.3.
21 Sodium, furfural and the fatty acids caprylic (C8:0), capric (C10:0), lauric (C12:0), myristic (C14:0), myristoleic (C14:1),
pentadecanoic (C15:0), pentadecenoic (C15:1), heptadecanoic (C17:0), heptadecenoic (C17:1), c-linolenic (C18:3),
eicosadienoic (C20:2), eicosatrienoic (C20:3) and arachidonic (C20:4).
22 Protein, moisture, ash, calcium, phosphorus, carbohydrates by calculation, total fat, acid detergent ﬁbre (ADF) and neutral
detergent ﬁbre (NDF).
23 Proximates (moisture, protein, total fat, ash, carbohydrates by calculation), ﬁbre fractions (acid detergent ﬁbre (ADF), neutral
detergent ﬁbre (NDF), total detergent ﬁbre (TDF)), amino acids (alanine, arginine, aspartic acid, cystine, glutamic acid,
glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine,
valine), fatty acids (palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid
(C18:2),linolenic acid (C18:3), arachidic acid (C20:0), eicosenoic acid (C20:1), behenic acid (C22:0)), vitamins (b-carotene,
thiamin, riboﬂavin, pyridoxine, a-tocopherol, niacin and folic acid), minerals (calcium, copper, iron, magnesium, manganese,
phosphorus, potassium and zinc) and other compounds (phytic acid, rafﬁnose, ferulic acid and p-coumaric acid).
24 Mean levels of ADF in forage (% DM): 24.38 (non-GM comparator); 25.80 (treated GM maize). DM: dry matter.
25 The forage constituents with signiﬁcantly different levels were calcium and moisture. The grain constituents with signiﬁcantly
different levels were: protein, total fat, carbohydrates by calculation, moisture, alanine, arginine, aspartic acid, cystine,
glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan,
tyrosine, valine, palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linolenic acid (C18:2),
arachidic acid (C20:0), eicosenoic acid (C20:1), folic acid, b-carotene, thiamin, riboﬂavin, pyridoxine, a-tocopherol, NDF, TDF,
copper, iron, magnesium, manganese, phosphorus, potassium, phytic acid, rafﬁnose, ferulic acid and p-coumaric acid.
26 The forage constituents with signiﬁcantly different levels were NDF, calcium and ash. The grain constituents with signiﬁcantly
different levels were: protein, total fat, carbohydrates by calculation, moisture, alanine, arginine, aspartic acid, cystine,
glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan,
tyrosine, valine, palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linolenic acid (C18:2),
arachidic acid (C20:0), eicosenoic acid (C20:1), folic acid, pyridoxine, thiamin, NDF, copper, iron, magnesium, manganese,
phosphorus, potassium, phytic acid, rafﬁnose, ferulic acid and p-coumaric acid.
27 Results for thiamin in grain (mg/kg DM) were as follows. Mean level for the non-GM comparator: 2.53; mean level for the
treated GM maize: 2.34; equivalence limits: (2.36, 4.19). DM: dry matter.
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changes observed, the GMO Panel did not identify any need for further food/feed safety assessment
except for the change in thiamin levels.
3.3.2.4. Conclusions of the comparative analysis
The GMO Panel concludes that, except for thiamin, none of the differences identiﬁed between
maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 and the non-GM comparator in
forage and grain composition and agronomic and phenotypic characteristics needs further assessment
regarding food and feed safety. The nutritional impact of the reduced thiamin levels in maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 is further discussed in Section 3.3.3.5.
Moreover, none of the differences identiﬁed in the agronomic and phenotypic characteristics tested
between maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 and the non-GM comparator
needs further assessment regarding its potential environmental impact.
3.3.3. Food and feed safety assessment
3.3.3.1. Effects of processing
Processed products
Maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 will undergo existing production
processes used for conventional maize. No novel production process is envisaged.
Newly expressed proteins
Effects of heat treatment on newly expressed proteins Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1,
Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS have been previously assessed by the GMO Panel in the
context of the single maize events (see Table 2).
3.3.3.2. Toxicology
Toxicological assessment of newly expressed proteins28
Eight proteins (Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS) are
newly expressed in maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 (Section 3.3.1).
The GMO Panel has previously assessed the safety of the Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1,
Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS proteins individually in the context of the single maize
events, and no safety concerns were identiﬁed for humans and animals (Table 2). The GMO Panel is
not aware of any new information that would change this conclusion.
The potential for a functional interaction between the proteins newly expressed in maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 was assessed with regard to human and
animal health. The two enzymes PAT and CP4 EPSPS catalyse distinct biochemical reactions and act on
unrelated substrates in the plant with high substrate speciﬁcity. The six insecticidal proteins
(Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1 and Cry35Ab1) act through cellular receptors found in
target insect species, and it is reported that the gastrointestinal tract of mammals, including humans,
lacks receptors with high speciﬁc afﬁnity to Cry proteins (Hammond et al., 2013; Koch et al., 2015).
On the basis of the known biological function of the individual newly expressed proteins (Table 4),
there is currently no expectation for possible interactions between the newly expressed proteins
relevant for food and feed safety. Since the individual proteins are considered safe for humans and
animals, the same conclusion can be extended to their presence in the ﬁve-event stack maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122.
The GMO Panel concludes that there are no safety concerns to human and animal health related to
the newly expressed proteins Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1, Cry35Ab1, CP4 EPSPS
and PAT in the ﬁve-event stack maize.
28 Dossier: Part II – Section A4.2.
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Toxicological assessment of components other than newly expressed proteins29
The ﬁve-event stack maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 does not
show any compositional difference with the non-GM comparator that would require further
toxicological assessment (Section 3.3.2).
3.3.3.3. Animal studies with the food/feed derived from GM plants
No animal studies with food/feed derived from maize MON 87427 9 MON 89034 9
1507 9 MON 88017 9 59122 were provided by the applicant (e.g. 90-day toxicity feeding studies in
rodents or feeding studies in young rapidly growing animal species).
The decrease in thiamin was considered not to give rise to a substantial modiﬁcation in the
composition of the food and feed derived from the ﬁve-event stack maize (Sections 3.3.2 and 3.3.3.5).
Furthermore, no indication for potential occurrence of unintended effects based on the molecular,
compositional or phenotypic analyses, and no indication of possible interactions between the events
were identiﬁed (Sections 3.3.1 and 3.3.2). Therefore, no animal studies on the food and feed derived
from maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 are required (EFSA GMO
Panel, 2011a).
3.3.3.4. Allergenicity
For the allergenicity assessment, a weight-of-evidence approach was followed, taking into account
all of the information obtained on the newly expressed proteins, as no single piece of information or
experimental method yields sufﬁcient evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA
GMO Panel, 2011a). In addition, when known functional aspects of the newly expressed protein or
structural similarity to known adjuvants may indicate an adjuvant activity, the possible role of these
proteins as adjuvants is considered. When newly expressed proteins with a potential adjuvant activity
are expressed together, possible interactions increasing adjuvanticity and impacting the allergenicity of
the GM crop are assessed.
Assessment of allergenicity of the newly expressed proteins30
For allergenicity, the GMO Panel has previously evaluated the safety of the Cry1A.105, Cry2Ab2,
Cry1F, Cry3Bb1, Cry34Ab1, Cry35Ab1, PAT and CP4 EPSPS proteins individually, and no concerns on
allergenicity were identiﬁed in the context of the applications assessed (see Table 2). No new
information on allergenicity of these proteins that might change the previous conclusions of the GMO
Panel has become available. Based on the current knowledge, and as none of the newly expressed
proteins showed allergenicity, no reasons for concerns regarding the simultaneous presence of these
newly expressed proteins in the ﬁve-event stack maize affecting their allergenicity were identiﬁed.
For adjuvanticity, proteins derived from B. thuringiensis (Bt proteins) have been suggested to possess
adjuvant activity based on animal studies on Cry1Ac when applied at relatively high doses (e.g. Vazquez
et al., 1999). The Panel has previously evaluated the safety of the Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1,
Cry34Ab1 and Cry35Ab1 proteins and no concerns on adjuvanticity were identiﬁed in the context of the
applications assessed (see Table 2). The levels of individual Bt proteins in the ﬁve-event stack maize are
similar to those in the respective single maize events (see Appendix A). From the limited experimental
evidence available, the GMO Panel did not ﬁnd indications that the presence of the Bt proteins at the
levels expressed in the ﬁve-event stack maize might act as adjuvants with the potential to enhance a
speciﬁc immunoglobulin E (IgE) response and to favour the development of an allergic reaction.
Assessment of allergenicity of GM plant products31
The GMO Panel regularly reviews the available publications on food allergy to maize. However, to
date, maize has not been considered to be a common allergenic food32 (OECD, 2002). Therefore, the
GMO Panel did not request experimental data to analyse the allergen repertoire of GM maize.
29 Dossier: Part II – Section A4.3.
30 Dossier: Part II – Sections A5.1 and A5.3.
31 Dossier: Part II – Section A5.2.
32 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004.
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In the context of this application, and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins (see Sections 3.3.1, 3.3.2
and 3.3.3.2), the GMO Panel identiﬁed no indications of a potentially increased allergenicity of food
and feed derived from the ﬁve-event stack maize with respect to that derived from the non-GM
comparator.
3.3.3.5. Nutritional assessment of GM food/feed
The intended traits of maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 are
herbicide tolerance and insect resistance, with no intention to alter nutritional parameters. Comparison
of the composition of the ﬁve-event stack maize with that of the non-GM comparator and the non-GM
commercial reference varieties identiﬁed a decrease of thiamin (approximately 8%) in grains of the
ﬁve-event stack maize that required further nutritional assessment (see Section 3.3.2).
The nutritional implications in humans of the decrease of thiamin were assessed based on the fact
that grain and grain-based products are among the main contributors to thiamin intake across different
age classes. As an example, the contribution of this food group can represent up to 40% of the total
intake of thiamin in the adult population (EFSA NDA Panel, 2016). The GMO Panel performed a detailed
evaluation of the particular contribution of maize and maize-based products to the total intake of
thiamin using consumption data from the EFSA Comprehensive Food Consumption database33 (EFSA,
2011a) and the EFSA nutrient composition database.34 This assessment showed that the average
contribution of maize and maize-based products to the thiamin intake is rather limited, with an
estimated range in adults between 0.2% and 5.5% across different European countries.
Considering the extent of the decrease and, above all, the limited role of maize and maize-based
products in the intake of thiamin, the GMO Panel concludes that the nutritional impact of the foods
derived from the ﬁve-event stack maize is similar to that expected from the non-GM comparator and
non-GM commercial reference varieties.
Regarding feed, thiamin is synthesized in the gastrointestinal tract of some animals and, moreover,
the feed is balanced for vitamins with vitamin premixes. Therefore, the GMO Panel also considers that
the nutritional impact of the feed derived from the ﬁve-event stack maize is similar to that expected
from the non-GM comparator and non-GM commercial varieties.
3.3.3.6. Conclusion of the food and feed safety assessment
The newly expressed proteins Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1, Cry35Ab1, PAT and
CP4 EPSPS in maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 do not raise safety
concerns for human and animal health. No interactions between these newly expressed proteins
relevant for food and feed safety were identiﬁed. Similarly, the GMO Panel did not identify indications
of safety concerns regarding allergenicity or adjuvanticity related to the presence of the newly
expressed proteins in maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122, or regarding
the overall allergenicity of the ﬁve-event stack maize. The ﬁve-event stack maize is as safe and
nutritious as the non-GM comparator and the non-GM commercial reference varieties tested.
3.3.4. Environmental risk assessment
Considering the scope of application EFSA-GMO-BE-2013-118 (which excludes cultivation), the ERA
of the maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 is mainly concerned with:
(1) the exposure of bacteria to recombinant DNA in the gastrointestinal tract of animals fed GM
material and bacteria present in environments exposed to faecal material of these animals (manure
and faeces) and (2) the accidental release into the environment of viable GM maize grains during
transportation and/or processing (EFSA GMO Panel, 2010a).
3.3.4.1. Persistence and invasiveness of the GM plant35
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the European environment without appropriate management. Occasional feral GM maize
plants may occur outside cultivation areas (e.g. Han et al., 2015; Pascher, 2016), but survival is limited
33 Thirteen dietary surveys from nine countries were used in the assessment; the dietary surveys were classiﬁed according to
FoodEx2 classiﬁcation (EFSA, 2011b).
34 EFSA nutrient composition database was compiled as a deliverable of the EFSA procurement project ‘Updated food
composition database for nutrient intake’ (Roe et al., 2013).
35 Dossier: Part II – Section E3.1.
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mainly by a combination of low competitiveness, absence of a dormancy phase and susceptibility to
plant pathogens, herbivores and cold climate conditions. In ﬁelds within the EU, maize volunteers may
arise under some environmental conditions (mild winters). Field observations indicate that maize grains
may survive and overwinter in some regions, resulting in volunteers in subsequent crops (e.g. Gruber
et al., 2008; Palaudelmas et al., 2009; Pascher, 2016). However, maize volunteers in the EU have been
shown to grow weakly and ﬂower asynchronously with the maize crop (Palaudelmas et al., 2009).
As described in Section 3.3.2.2, ﬁeld trials were performed in the US in the 2010 growing season to
assess the agronomic/phenotypic characteristics of the ﬁve-event stack maize in comparison with the
non-GM comparator. The data showed no changes in agronomic and phenotypic plant characteristics
that would indicate altered ﬁtness, persistence and invasiveness of the ﬁve-event stack maize.
Considering the agronomic and phenotypic characteristics of the ﬁve-event stack maize and the
general characteristics of maize described above, there are no indications of an increased likelihood of
establishment and spread of occasional feral GM maize plants harbouring any combination of the ﬁve
events of which it is composed. Should these plants be exposed to glyphosate- or glufosinate-
containing herbicides, or infested by insect pests that are susceptible to the Cry1A.105, Cry2Ab2,
Cry1F, Cry3Bb1, Cry34Ab1 or Cry35Ab1 proteins, they are likely to exhibit a selective advantage that
could increase their local occurrence. However, considering maize vulnerability to several abiotic and
biotic factors, this occurrence is expected to be transient and will not result in different environmental
impacts compared to conventional maize.
In addition to the data presented by the applicant, the GMO Panel is not aware of any scientiﬁc
report of increased spread, establishment and survival capacity of the ﬁve-event stack maize or maize
with comparable properties. Therefore, the GMO Panel concludes that it is unlikely that
maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 would differ from conventional
maize varieties in its ability to survive until subsequent seasons under European environmental
conditions, if there was accidental release of viable GM maize grains into the environment.
3.3.4.2. Potential for gene transfer36
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through HGT of DNA, or through vertical gene ﬂow via cross-pollination from feral
plants originating from spilled grains.
Plant-to-microorganism gene transfer
The potential for HGT of the recombinant DNA of the single events has been assessed in previous
GMO Panel Scientiﬁc Opinions (see Table 2) and no concern as a result of an unlikely, but theoretically
possible, HGT of the recombinant genes to bacteria in the gut of animal fed GM material or other
receiving environments was identiﬁed. The applicant submitted an independent updated bioinformatic
analysis for each of the single events in order to assess possibility for HGT by HR (Section 3.2).
Bioinformatic analysis of event MON 87427 revealed two elements that could provide sufﬁcient
length and sequence identity which could facilitate HGT, i.e. the truncated left border of an
Agrobacterium tumefaciens octopine plasmid and the T-nos terminator of an A. tumefaciens nopaline
plasmid. Because these elements are located on different plasmids, the results of the bioinformatic
analysis give no indication for facilitated double HR.
Bioinformatic analysis of event MON 89034 revealed three elements that could provide sufﬁcient
length and sequence identity which could facilitate HGT. These are the truncated left border at 30 and
the one at 50 and the T-nos terminator. The homologies with A. tumefaciens at the left borders align to
the same region of the target sequences in an A. tumefaciens octopine plasmid but are inserted in the
plant genome in an opposite orientation. Therefore they are supporting double HR. The T-nos
terminator gives homology with an A. tumefaciens, nopaline plasmid and does not support double HR.
Bioinformatic analysis of event 1507 revealed that due to codon optimisation of the cry1F and pat
gene there was no sequence identity with bacterial genes and thus no indication for HR.
Bioinformatic analysis of event MON 88017 revealed that the two genetic elements encoding for
Cry3Bb1 and PAT were codon-optimised and did not provide sufﬁcient sequence identity to bacterial
DNA. However, four qualiﬁed alignments were detected with T-DNA from Ti plasmids of
A. tumefaciens. No paired alignments and thus no potential to facilitate double HR were identiﬁed.
Gene replacements of T-DNA-sequences on natural Ti plasmids, which are extremely unlikely due to an
36 Dossier: Part II – Sections E3.1 and E.3.2.
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expected absence of very low abundance of A. tumefaciens in the main receiving environments, i.e.
the gastrointestinal tract, would not confer any new trait or selective advantage to bacterial recipients.
Bioinformatic analysis of event 59122 revealed no sequence identity with bacterial DNA which
would facilitate HR, because the original bacterial genes encoding for Cry34Ab1, Cry35Ab1 and the
PAT protein were all codon-optimised for expression in plants.
Synergistic effects of the recombinant genes, for instance due to combinations of recombinogenic
sequences, which would cause an increase in the likelihood for HGT or a selective advantage were not
identiﬁed.
Based on the above information, the GMO Panel did not identify an increased likelihood for
horizontal transfer of recombinant genes to bacteria for the ﬁve-event stack maize. This is consistent
with its previous assessments of maize events MON 87427, MON 89034, 1507, MON 88017 and 59122.
Plant-to-plant gene transfer
Considering the scope of application EFSA-GMO-BE-2013-118 and the biology of maize, the
potential of occasional feral GM maize plants originating from grain import spills to transfer
recombinant DNA to sexually cross-compatible plants and the environmental consequences thereof
were considered. As pointed out above (Section 3.3.4.1), the occurrence of feral GM maize plants is
expected to be limited.
The extent of cross-pollination from occasional feral GM maize plants to other maize species will
mainly depend on accidental release during transportation and processing and on successful
establishment and subsequent ﬂowering of the GM maize plant. For maize, vertical gene transfer is
limited to Zea species. Populations of sexually compatible wild relatives of maize outside cultivation are
not known in Europe (Eastham and Sweet, 2002; OECD, 2003). Therefore, vertical gene transfer is not
considered to be an environmental issue in the EU.
The ﬂowering of occasional feral GM maize plants originating from accidental release during
transportation and processing is unlikely to lead to dispersal of signiﬁcant amounts of GM maize pollen
onto other maize plants. Field observations performed on maize volunteers after GM maize cultivation
in Spain revealed that maize volunteers had a low vigour, rarely had cobs and produced pollen that
cross-pollinated neighbouring plants only at low levels (Palaudelmas et al., 2009). Thus, the likelihood
of cross-pollination between cultivated maize and occasional feral maize plants resulting from grain
spillage is considered extremely low.
In conclusion, even if cross-pollination would occur, the GMO Panel is of the opinion that the
likelihood of environmental effects as a consequence of the spread of genes from occasional feral GM
maize plants in Europe will not differ from that of conventional maize varieties.
3.3.4.3. Interactions of the GM plant with target organisms37
Interactions might occur between different Cry proteins. Whether such an interaction takes place
depends on the arthropod species tested (EcoƩtat, 2014; De Schrijver et al., 2015). Considering the
scope of application EFSA-GMO-BE-2013-118, and the low level of exposure of the environment to this
GM maize, potential interactions of occasional feral GM plants arising from spilled grains with target
organisms are not considered a relevant issue by the GMO Panel.
3.3.4.4. Interactions of the GM plant with non-target organisms38
As mentioned in Section 3.3.4.3, interactions between Cry proteins, leading to synergistic
insecticidal effects, might occur in other susceptible non-target species. Considering that environmental
exposure of non-target organisms to stored GM grains, spilled GM grains or GM plants arising from
spilled GM grains is limited, potential exposure of non-target organisms sensitive to Cry1A.105,
Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1 and/or Cry35Ab1 proteins is likely to be very low.
The GMO Panel also evaluated whether the expressed Cry proteins might affect non-target organisms
by entering the environment through faecal material of animals fed GM maize. Cry proteins are degraded
by enzymatic activity in the gastrointestinal tract, meaning that only low amounts of intact Cry proteins
would remain in the faeces. This was demonstrated for Cry1Ab (Einspanier et al., 2004; Lutz et al.,
2005; Lutz et al., 2006; Wiedemann et al., 2006; Guertler et al., 2008; Paul et al., 2010). Further
degradation of the protein in the manure and faeces will take place because of microbiological
proteolytic activity. In addition, there will be further degradation of the expressed Cry proteins in soil,
37 Dossier: Part II – Section E3.3.
38 Dossier: Part II – Section E3.4.
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reducing the possibility for exposure of potentially sensitive non-target organisms. Although Cry proteins
may bind to clay minerals and organic substances in soil, thereby reducing their availability to
microorganisms for degradation, there are no indications of persistence and accumulation of Cry proteins
from GM crops in soil (Gruber et al., 2012; Valldor et al., 2015). The GMO Panel is not aware of evidence
of released Cry proteins from GM plants causing signiﬁcant negative effects on soil microorganisms.
Considering the scope of the application, it can be concluded that the exposure of potentially
sensitive non-target organisms to the Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1 and/or
Cry35Ab1 proteins is likely to be very low and that the risks related to interactions with non-target
organisms are therefore of no relevance.
3.3.4.5. Interactions with abiotic environment and biochemical cycles39
Considering the scope of application EFSA-GMO-BE-2013-118, and the low level of exposure to the
environment, potential interactions of spilled grains or occasional feral maize MON 87427 9
MON 89034 9 1507 9 MON 88017 9 59122 with the abiotic environment and biogeochemical cycles
are not considered a relevant issue by the GMO Panel.
3.3.4.6. Conclusion of the environmental risk assessment
There are no indications of an increased likelihood of establishment and spread of occasional feral
maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 plants in the case of accidental
release into the environment of viable grains, unless these plants are infested by insect pests that are
susceptible to the Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1 Cry34Ab1 and/or Cry35Ab1 proteins, or
exposed to glyphosate- and/or glufosinate-containing herbicides. However, the GMO Panel is of the
opinion that the possible exposure of feral GM plants to these herbicides or susceptible pests would
not result in different environmental impacts compared to conventional maize. Considering the scope
of application EFSA-GMO-BE-2013-118, interactions with the biotic and abiotic environment are not
considered to be relevant issues. Risks associated with an unlikely but theoretically possible HGT of
recombinant DNA from the ﬁve-event stack maize have not been identiﬁed. Therefore, considering the
novel combination of events, the introduced traits, the outcome of the comparative analysis, the
routes of exposure and the limited exposure levels, the GMO Panel concludes that maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 would not raise safety concerns in the
event of accidental release of viable GM maize grains into the environment.
3.3.5. Conclusion on the ﬁve-event stack maize MON 87427 3 MON 89034 3
1507 3 MON 88017 3 59122
No new data on the single maize events MON 87427, MON 89034, 1507, MON 88017 and 59122
leading to a modiﬁcation of the original conclusions on their safety were identiﬁed.
The combination of maize events MON 87427, MON 89034, 1507, MON 88017 and 59122 in the
ﬁve-event stack maize did not give rise to issues pertaining to the molecular, agronomic/phenotypic or
compositional characteristics of the ﬁve-event stack maize that would be of concern for food and feed
safety and nutrition.
The newly expressed proteins in the ﬁve-event maize do not raise safety concerns for human and
animal health and the environment in light of the scope of this application.
No indications of interactions between the events based on the biological functions of the newly
expressed proteins that would raise a safety issue were identiﬁed in maize MON 87427 9 MON
89034 9 1507 9 MON 88017 9 59122. Comparison of the levels of the newly expressed proteins
between the ﬁve-event stack maize and those of the single maize events did not reveal an interaction
at the protein expression level.
Considering the combined events and the outcome of the comparative analysis, the routes of
exposure and limited exposure levels, the EFSA GMO Panel concludes that maize MON 87427 9 MON
89034 9 1507 9 MON 88017 9 59122 would not raise safety concerns in the event of accidental
release of viable GM maize grains into the environment.
No scientiﬁc information that could change the conclusions on the ﬁve-event stack maize was
retrieved in a literature search covering the period since the time of validity of the application. The
GMO Panel concludes that maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 is as
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safe and as nutritious as the non-GM comparator and the non-GM commercial reference varieties in
the context of its scope.
3.4. Risk assessment of the subcombinations
The GMO Panel Guidance Documents establish the principle that ‘where all single events have been
assessed, the risk assessment of stacked events focuses on issues related to: (a) stability of the
events; (b) expression of the events; and (c) potential interactions between the events’ (EFSA GMO
Panel, 2011a).
For those subcombinations for which no speciﬁc data have been submitted and which have not been
previously assessed by the GMO Panel (see Table 7), the risk assessment takes as its starting point the
assessment of the single maize events MON 87427, MON 89034, 1507, MON 88017 and 59122 and uses
the data generated for the ﬁve-event stack maize, as well as all the additional data available on maize
subcombinations of these single events that were previously assessed by the GMO Panel (see Table 2).
3.4.1. Subcombinations previously assessed
The GMO Panel has previously assessed the two-event maize stacks 1507 9 59122 and
MON 89034 9 MON 88017 and no safety concerns were identiﬁed (EFSA GMO Panel, 2009b, EFSA
GMO Panel, 2010b). In addition, the GMO Panel has already assessed the four-event stack maize
MON 89034 9 1507 9 MON 88017 9 59122 and all its subcombinations independently of their origin
(see Table 2) and did not identify any safety concerns (EFSA GMO Panel, 2010c). Moreover, no
scientiﬁc information relevant to the risk assessment of these maize stacks became available since the
validation of application EFSA-GMO-BE-2013-118. Consequently, the GMO Panel considers that its
previous conclusions on these subcombinations remain valid.
3.4.2. Subcombinations not previously assessed
Fourteen out of 25 subcombinations included in the scope of this application have not been
previously assessed by the GMO Panel, and no experimental data were provided for these maize stacks
(see Table 7).
3.4.2.1. Stability of the events
The genetic stability of the inserted DNA over multiple generations in the ﬁve single maize events
was demonstrated previously (see Table 2). Integrity of the events was demonstrated in the ﬁve-event
stack maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 (Section 3.3.1.2) and the
previously assessed maize subcombinations (EFSA GMO Panel, 2009b, EFSA GMO Panel, 2010b,c). The
GMO Panel ﬁnds no reasons to expect the loss of integrity of the events in the maize subcombinations
not previously assessed (see Table 7).
Table 7: Maize stacks not previously assessed and covered by the scope of application EFSA-GMO-
BE-2013-118
Degree of stacking Events
Four-event stack maize MON 87427 9 1507 9 MON 88017 9 59122
MON 87427 9 MON 89034 9 1507 9 59122
MON 87427 9 MON 89034 9 1507 9 MON 88017
MON 87427 9 MON 89034 9 MON 88017 9 59122
Three-event stack maize MON 87427 9 1507 9 59122
MON 87427 9 1507 9 MON 88017
MON 87427 9 MON 88017 9 59122
MON 87427 9 MON 89034 9 1507
MON 87427 9 MON 89034 9 59122
MON 87427 9 MON 89034 9 MON 88017
Two-event stack maize MON 87427 9 1507
MON 87427 9 59122
MON 87427 9 MON 88017
MON 87427 9 MON 89034
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3.4.2.2. Expression of the events
The GMO Panel assessed whether the combination of any of the ﬁve events by conventional
crossing could result in signiﬁcant changes in expression levels of the newly expressed proteins, as this
could indicate an unexpected interaction between the events. Based on current knowledge of the
molecular elements introduced, there is no reason to expect interactions that would affect the levels of
the newly expressed proteins in the subcombinations compared with those in the single maize events.
This assumption was conﬁrmed by comparing the levels of the newly expressed proteins of each single
maize event with those of the ﬁve-event stack maize. The levels were similar in the ﬁve-event stack
maize and in the single events except for CP4 EPSPS and PAT, which showed the expected higher
levels in the stack resulting from the combination of the MON 87427 and MON 88017 events both
producing CP4 EPSPS protein, and 1507 and 59122 events both producing PAT protein
(Section 3.3.1.3 and Appendix A). Therefore, there was no indication of an interaction manifesting at
protein expression level. In addition, expression data from the two-event maize stacks 1507 9 59122
and MON 89034 9 MON 88017 (EFSA GMO Panel, 2009b, EFSA GMO Panel, 2010b) and the four-
event stack maize MON 89034 9 1507 9 MON 88017 9 59122 (EFSA GMO Panel, 2010c) were similar
to those observed in each of the single maize events or showed the expected higher levels for PAT
resulting from the combination of 1507 and 59122 events both producing PAT protein in the four-
event stack maize MON 89034 9 1507 9 MON 88017 9 59122. This conﬁrms that interactions
affecting expression levels of the newly expressed proteins are not expected in the 14 maize
subcombinations not previously assessed and included in the scope of application EFSA-GMO-BE-2013-118.
3.4.2.3. Potential functional interactions between the events
The GMO Panel assessed the potential interactions between events, due to their combination in the
subcombinations not previously assessed and included in the scope of application EFSA-GMO-BE-2013-118
(Table 7), taking into consideration intended traits and unintended effects.
Based on the known biological functions of the individual newly expressed proteins (Table 4), there
is currently no expectation for possible interactions between these proteins in the 14 subcombinations
not previously assessed relevant for the food and feed and environmental safety. The GMO Panel took
into account all the intended and potential unintended effects considered in the assessment of the ﬁve
single events, the previously assessed subcombinations (Table 2) and the ﬁve-event stack maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122. It was concluded that none of these
effects would raise safety concerns when combined in any of these maize subcombinations.40
Therefore, the GMO Panel is of the opinion that no additional data are needed to complete the
assessment of subcombinations from the ﬁve-event stack maize.
3.4.3. Conclusion
Since no new safety concerns were identiﬁed for the previously assessed two-event maize stacks
1507 9 59122 and MON 89034 9 MON 88017 as well as the four-event stack maize MON
89034 9 1507 9 MON 88017 9 59122 and all its subcombinations, the GMO Panel considers that its
previous conclusions on these maize subcombinations remain valid. For the remaining 14
subcombinations included in the scope of application EFSA-GMO-BE-2013-118 for which no
experimental data have been provided, the GMO Panel assessed the possibility of interactions between
the events and concluded that these combinations would not raise safety concerns. These
subcombinations are therefore expected to be as safe as the single maize events, the previously
assessed two-event maize stacks 1507 9 59122 and MON 89034 9 MON 88017 and the four-event
stack maize MON 89034 9 1507 9 MON 88017 9 59122 including all its subcombinations as well as
the ﬁve-event stack maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122.
40 15th GMO Panel meeting (Annex 1 of the minutes: http://www.efsa.europa.eu/sites/default/files/event/170517-m.pdf)
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3.5. Post-market monitoring
3.5.1. Post-market monitoring of GM food/feed
There was no indication that food/feed products derived from the ﬁve-event stack maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 are less safe or nutritious than those derived
from the non-GM comparator. Furthermore, the overall intake or exposure is not expected to change
because of the introduction of maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 into the
market.
The two-event maize stacks 1507 9 59122 and MON 89034 9 MON 88017 as well as the four-event
stack maize MON 89034 9 1507 9 MON 88017 9 59122 and all its subcombinations have been
previously assessed and no safety concerns were identiﬁed. The 14 subcombinations not previously
assessed and included in the scope of application EFSA-GMO-BE-2013-118 are expected to be as safe as
the single maize events, the previously assessed maize subcombinations and the ﬁve-event stack maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122. Therefore, the GMO Panel considers that
post-market monitoring of maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 and its
subcombinations is not necessary.
3.5.2. Post-market environmental monitoring41
The objectives of a PMEM plan, according to Annex VII of Directive 2001/18/EC are: (1) to conﬁrm
that any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or
its use, in the ERA are correct and (2) identify the occurrence of adverse effects of the GMO, or its
use, on human health or the environment that were not anticipated in the ERA.
Monitoring is related to risk management, and thus a ﬁnal adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientiﬁc content of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA did not identify potential adverse environmental effects from the ﬁve-event stack maize,
no case-speciﬁc monitoring is required.
The PMEM plan proposed by the applicant for the ﬁve-event stack maize includes: (1) the description
of a monitoring approach involving operators (federations involved in import and processing), reporting
to the applicant, via a centralised system, any observed adverse effect(s) of GMOs on human health and
the environment; (2) a coordinating system established by EuropaBio for the collection of information
recorded by the various operators; and (3) the review of relevant scientiﬁc publications retrieved from
literature searches (Lecoq et al., 2007; Windels et al., 2008). The applicant proposes to submit a PMEM
report on an annual basis and a ﬁnal report at the end of the authorisation period.
The GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the scope of maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122. As the scope
does not cover cultivation and potential adverse environmental effects from the ﬁve-event stack maize
were not identiﬁed, no case-speciﬁc monitoring is necessary. The GMO Panel agrees with the reporting
intervals proposed by the applicant in its PMEM plan. However, the PMEM plan submitted by the
applicant for the ﬁve-event stack maize does not include any provisions for the subcombinations not
previously assessed by the GMO Panel. Therefore, the GMO Panel recommends the applicant to revise
the plan accordingly.
4. Overall conclusions and recommendations
No new data on the ﬁve single maize events MON 87427, MON 89034, 1507, MON 88017 and
59122 that would lead to a modiﬁcation of the original conclusions on their safety were identiﬁed.
The combination of the events MON 87427, MON 89034, 1507, MON 88017 and 59122 in the ﬁve-
event stack maize did not give rise to issues relating to molecular, agronomic/phenotypic and
compositional characteristics regarding food and feed safety or nutrition. The newly expressed proteins
in the ﬁve-event stack maize did not raise concerns for human and animal health. Maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 is expected to be as nutritious as the
non-GM comparator and the tested non-GM maize commercial reference varieties.
Considering the combined events, the outcome of the comparative analysis and the routes
and levels of exposure, the GMO Panel concludes that maize MON 87427 9 MON 89034 9
41 Dossier: Part II – Section E4; additional information: 13/12/2016.
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1507 9 MON 88017 9 59122 would not raise environmental safety concerns in the event of accidental
release of viable GM maize grains into the environment.
The GMO Panel concludes that maize MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122
is as safe and as nutritious as the non-GM comparator and the tested non-GM maize reference
varieties in the context of the scope of this application.
Since no new data on the previously assessed two-event maize stacks 1507 9 59122 and MON
89034 9 MON 88017 and the four-event stack maize MON 89034 9 1507 9 MON 88017 9 59122
and its subcombinations that would lead to a modiﬁcation of the original conclusions on their safety
were identiﬁed, the GMO Panel considers that its previous conclusions on these maize stacks remain
valid. For the additional 14 maize subcombinations included in the scope of application EFSA-GMO-BE-
2013-118 for which no experimental data have been provided (Table 7), the GMO Panel assessed
possible interactions between the events, and concludes that combinations of the events MON 87427,
MON 89034, 1507, MON 88017 and 59122 would not raise safety concerns in these maize
subcombinations. These subcombinations are therefore expected to be as safe and as nutritious as the
single maize events, all the previously assessed subcombinations and the ﬁve-event stack maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122.
Given the absence of safety concerns for food and feed derived from the ﬁve-event stack maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 and all its subcombinations, the GMO
Panel considers that post-market monitoring of these products is not necessary.
The GMO Panel considers that the scope of the PMEM plans provided by the applicant is consistent
with the scope of the ﬁve-event stack maize and the already assessed subcombinations. The GMO
Panel agrees with the reporting intervals proposed by the applicant in the PMEM plans. However, the
PMEM plan submitted by the applicant for the ﬁve-event stack maize does not include any provisions
for the 14 subcombinations that were not previously assessed. Therefore, the GMO Panel recommends
the applicant to revise the plan accordingly.
Documentation as provided to EFSA
1) Letter from the Competent Authority of Belgium received on 26 November 2013 concerning
a request for placing on the market of genetically modiﬁed maize MON 87427 9 MON
89034 9 1507 9 MON 88017 9 59122 submitted by Monsanto Europe S.A./N.V. in
accordance with Regulation (EC) No 1829/2003 (application reference EFSA-GMO-BE-2013-
118).
2) Acknowledgement letter dated 3 December 2013 from EFSA to the Competent Authority of
Belgium.
3) Letter from EFSA to applicant dated 17 January 2014 requesting additional information
under completeness check.
4) Letter from applicant to EFSA received on 17 February 2014 providing additional
information under completeness check.
5) Letter from EFSA to applicant dated 10 March 2014 delivering the ‘Statement of Validity’ of
application EFSA-GMO-BE-2013-118 for placing on the market of genetically modiﬁed maize
MON 87427 9 MON 89034 9 1507 9 MON 88017 9 59122 submitted by Monsanto Europe
S.A./N.V. in accordance with Regulation (EC) No 1829/2003.
6) Letter from EFSA to applicant dated 11 June 2015 requesting additional information and
stopping the clock.
7) Letter from applicant to EFSA received on 6 July 2015 providing additional information.
8) Letter from EFSA to applicant dated 30 July 2015 requesting additional information and
maintaining the clock stopped.
9) Letter from applicant to EFSA received on 2 October 2015 providing additional information.
10) Letter from EFSA to applicant dated 26 November 2015 requesting additional information
and maintaining the clock stopped.
11) Letter from EFSA to applicant dated 11 December 2015 requesting additional information
and maintaining the clock stopped.
12) Letter from applicant to EFSA received on 18 December 2015 providing additional
information.
13) Letter from EFSA to applicant dated 8 March 2016 requesting additional information and
maintaining the clock stopped.
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14) Letter from applicant to EFSA, received on 8 June 2016 extending the timeline for
submission of responses.
15) Letter from applicant to EFSA received on 13 June 2016 providing additional information.
16) Letter from EFSA to applicant dated 28 June 2016 requesting additional information and
maintaining the clock stopped.
17) Letter from applicant to EFSA received on 11 July 2016 providing additional information.
18) Letter from applicant to EFSA received on 29 July 2016 providing additional information.
19) Email from EFSA to applicant, dated 29 July 2016, re-starting the clock.
20) Letter from EFSA to applicant dated 4 August 2016 requesting additional information and
stopping the clock.
21) Letter from EFSA to applicant dated 11 August 2016 requesting additional information and
maintaining the clock stopped.
22) Letter from applicant to EFSA received on 1 September 2016 providing additional
information.
23) Letter from applicant to EFSA received on 15 September 2016 providing additional
information.
24) Letter from EFSA to applicant dated 25 October 2016 requesting additional information and
maintaining the clock stopped.
25) Letter from applicant to EFSA received on 24 November 2016 providing additional
information.
26) Letter from applicant to EFSA received on 25 November 2016 providing additional
information. This package included spontaneous information.
27) Email from EFSA to applicant, dated 29 November 2016, re-starting the clock from 25
November 2016.
28) Letter from applicant to EFSA received on 13 December 2016 providing Updated PMEM,
Cartagena, Labelling and Summary of application spontaneously.
29) Letter from EFSA to applicant dated 11 April 2017 requesting additional information and
stopping the clock.
30) Letter from EFSA to applicant dated 16 May 2017 requesting additional information and
maintaining the clock stopped.
31) Letter from applicant to EFSA received on 6 June 2017 providing additional information.
32) Letter from applicant to EFSA received on 20 June 2017 providing additional information.
33) Email from EFSA to applicant, dated 20 June 2016, re-starting the clock.
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Appendix A – Protein expression data
Means, standard deviation and ranges of protein levels (lg/g dry weight) from maize MON
87427 9 MON 89034 9 1507 9 MON 88017 9 59122 (treated with glyphosate and glufosinate), MON
87427 (treated with glyphosate), MON 89034 (not treated), 1507 (treated with glufosinate), MON 88017
(treated with glyphosate) and 59122 (treated with glufosinate) from ﬁeld trials performed in the US in 2010.
MON 87427 3
MON 89034 3
1507 3 MON
88017 3 59122
MON
87427
MON
89034
1507
MON
88017
59122
Cry1A.105
Leaf (V2–V4) 300(a)  61(b)
(230–420)(c)
290  82
(150–390)
Root (V2–V4) 83  27
(49–140)
56  11
(42–76)
Root (R5) 14  3.3
(7.8–19)
12  3.7
(7.5–20)
Whole Plant
(V10–V12)
58  12
(38–81)
53  9.1
(37–73)
Forage (R5) 32  8.6
(16–45)
23  6.2
(9.2–32)
Pollen
(pollination)
14  2.5
(10–19)
5.5  4.3
(2.8–22)
Grain (R6) 8.1  2.4
(6.0–14)
5.9  1.0
(4.3–7.9)
Cry2Ab2
Leaf (V2–V4) 260  78
(110–390)
220  52
(92–350)
Root (V2–V4) 40  13
(23–72)
32  8.7
(22–57)
Root (R5) 17  7.9
(3.1–30)
19  7.6
(7.7–33)
Whole Plant
(V10–V12)
50  11
(29–66)
32  5.7
(18–39)
Forage (R5) 39  10
(17–58)
32  8.5
(16–53)
Pollen
(pollination)
0.33  0.11
(0.19–0.66)
0.31  0.12
(0.18–0.52)
Grain (R6) 1.8  0.40)
(1.2–2.8)
1.6  0.61
(0.96–3.8)
Cry1F
Leaf (V2–V4) 20  3.7
(15–28)
17  7.1
(11–42)
Root (V2–V4) 10  3.3
(5.0–17)
8.8  2.9
(4.6–15)
Root (R5) 2.7  0.69
(1.5–3.8)
2.8  0.67
(1.7–3.8)
Whole Plant
(V10–V12)
9.6  1.6
(6.9–13)
8.3  2.2
(5.3–12)
Forage (R5) 5.0  1.2
(3.1–7.3)
4.8  1.1
(3.2–6.4)
Pollen
(pollination)
12  1.5
(9.6–16)
11  1.4
(8.8–14)
Grain (R6) 2.0  0.33
(1.6–2.8)
1.8  0.22
(1.4–2.1)
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MON 87427 3
MON 89034 3
1507 3 MON
88017 3 59122
MON
87427
MON
89034
1507
MON
88017
59122
Cry3Bb1
Leaf (V2–V4) 260  39
(200–320)
250  40
(190–320)
Root (V2–V4) 150  32
(97–220)
150  35
(110–210)
Root (R5) 51  14
(31–84)
77  17
(44–110)
Whole Plant
(V10–V12)
120  30
(76–200)
110  20
(69–140)
Forage (R5) 50  11
(30–69)
50  14
(33–75)
Pollen
(pollination)
14  2.3
(11–19)
12  2.1
(4.4–14)
Grain (R6) 7.8  1.1
(6.1–9.6)
9.5  0.87
(7.5–11)
Cry34Ab1
Leaf (V2–V4) 53  16
(27–85)
40  9.1
(24–54)
Root (V2–V4) 67  26
(26–130)
62  28
(21–120)
Root (R5) 39  15
(12–76)
38  13
(11–58)
Whole Plant
(V10–V12)
61  17
(29–96)
84  52
(33–210)
Forage (R5) 99  23
(66–160)
73  23
(47–140)
Pollen
(pollination)
72  7.2
(57–88)
92  13
(74–120)
Grain (R6) 35  4.3
(29–42)
29  5.3
(21–39)
Cry35Ab1
Leaf (V2–V4) 19  6.2
(11–33)
16  5.3
(5.3–27)
Root (V2–V4) 18  8.0
(6.2–36)
19  8.1
(3.9–34)
Root (R5) 3.0  1.6
(0.69–7.4)
3.4  1.8
(0.63–6.5)
Whole Plant
(V10–V12)
18  4.1
(7.8–26)
15  3.9
(8.6–24)
Forage (R5) 12  3.2
(6.9–18)
11  3.3
(6.7–20)
Pollen
(pollination)
< LOQ  NA
(< LOD–0.65)
<LOQ  NA
(<LOD–0.67)
Grain (R6) 0.55  0.11
(0.39–0.80)
0.62  0.17
(0.42–0.86)
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MON 87427 3
MON 89034 3
1507 3 MON
88017 3 59122
MON
87427
MON
89034
1507
MON
88017
59122
PAT
Leaf (V2–V4) 8.4  2.5
(4.0–14)
1.9  0.53
(1.1–2.8)
8.0  1.7
(4.9–11)
Root (V2–V4) 1.7  0.62
(0.66–2.9)
0.43  0.31
(0.083–1.5)
1.2  0.37
(0.51–1.7)
Root (R5) 0.42  0.19)
(0.10–0.72)
0.15  0.053
(0.063–0.25)
0.26  0.14
(0.061–0.53)
Whole Plant
(V10–V12)
4.3  1.4
(2.8–8.0)
1.1  0.45
(0.57–2.2)
3.2  1.1
(1.7–6.0)
Forage (R5) (0.85  0.30)
(0.17–1.1)
0.26  0.088
(0.15–0.41)
0.76  0.31
(0.19–1.2)
Pollen
(pollination)
< LOD(d) < LOD < LOD
Grain (R6) < LOD < LOD < LOD
CP4 EPSPS
Leaf (V2–V4) 770  100
(550–910)
780  170
(540–1100)
210  33
(150–270)
Root (V2–V4) 200  53
(130–320)
130  35
(85–230)
57  12
(41–78)
Root (R5) 77  28
(26–160)
60  21
(30–100)
14  5.1
(6.9–26)
Whole Plant
(V10–V12)
380  58
(270–480)
320  56
(240–430)
80  14
(49–100)
Forage (R5) 190  50
(100–270)
140  57
(62–270)
36  13
(23–67)
Pollen
(pollination)
310  66
(220–440)
< LOQ(e) 180  47
(62–290)
Grain (R6) 7.6  1.1
(5.8–11)
4.9  1.2
(2.7–7.1)
4.2  1.1
(2.5–6.6)
(a): Mean.
(b): Standard deviation.
(c): Range.
(d): LOD: limit of detection; LOQ: limit of quantiﬁcation.
(e): Due to speciﬁc insert design, little to no CP4 EPSPS protein is expected to be produced in pollen.
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